AIFD Publishes Comprehensive Analysis of Value-Based Reimbursement Systems: New Report Tailored to Türkiye’s Needs
08.06.2026
The “Sustainable Value-Based Pharmaceutical Pricing and Reimbursement Report Designed for Türkiye’s Needs,” prepared by IQVIA at the initiative of AIFD and the European Federation of Pharmaceutical Industries and Associations (EFPIA), has been released to the public. The report provides a comprehensive reference for policy dialogue on value-based pricing and reimbursement systems.
The “Sustainable Value-Based Pharmaceutical Pricing and Reimbursement Report Designed for Türkiye’s Needs,” prepared by IQVIA at the initiative of AIFD, was presented to the public at a panel held on June 7, 2026, as part of the HTAi Annual Meeting in Istanbul. The report approaches the concept of value in healthcare through a multidimensional framework and was prepared with the aims of raising knowledge and awareness regarding the increasingly prevalent value-based approach in pharmaceutical pricing and reimbursement processes, demonstrating the need for a model that facilitates patient access to medicinal products while ensuring financial sustainability for payers, and offering recommendations on the applicability of this approach in the context of Türkiye.
A Resource to Act as Reference for the Roadmap to Value-Based Systems
The “value” concept, which has evolved since the 1980s alongside the measurement of health outcomes, is gaining increasing prominence in pharmaceutical pricing and reimbursement policies today. Alongside clinical efficacy and safety, the assessment of the total value that medicines deliver to patients, society, and payers is considered critical for the sustainability of health systems.
Focused on developing value-based reimbursement methods in Türkiye, the report offers an analytical approach to the holistic assessment of the relationship between clinical benefit, health outcomes, and resource utilization. It develops policy recommendations aligned with the objectives set out in the Twelfth Development Plan and the Medium-Term Program, including enhancing the effectiveness of the reimbursement system, implementing evidence-based models, and strengthening the assessment infrastructure for health expenditures.
Commenting on the report, AIFD Board Chairman Cem Öztürk stated: “Value-based health systems offer a more holistic decision-making approach that evaluates not only cost, but clinical benefit, economic sustainability, and societal impact together. As AIFD, we regard this area of transformation, also reflected in the Twelfth Development Plan, as one of our sector’s foremost areas of responsibility. Guided by the will of public authorities and placing Türkiye’s needs at the center, this report prepared by IQVIA at the initiative of AIFD and EFPIA creates a common platform for discussion, laying out the experiences of different countries, the existing structure in Türkiye, and how ‘the value of medicinal products’ can be defined from a stakeholder perspective. This is precisely where the core role of Health Technology Assessment begins: making clinical, economic, and societal impact visible, and supporting value-based decision-making processes that consider both patient access and system sustainability. We are pleased to contribute to the multi-stakeholder dialogue in this field.”
AIFD Secretary General Dr. Ümit Dereli offered the following assessment of the report: “International discussions in the field of health technology assessment show that we need to approach the concept of value in healthcare from a much broader perspective. The ‘Value Flower’ approach goes beyond clinical benefit and cost, enabling us to holistically consider a patient’s quality of life, disease burden, impact on family and society, productivity, equity, disease severity, and contribution to scientific progress. This perspective also has strong resonance at the academic level. For both scientific robustness and applicability, it is critically important that value-based HTA policies in Türkiye be shaped through joint contributions from the public sector, academia, patient representatives, healthcare professionals, and the industry.”
The report’s editor, Assoc. Prof. Dr. Elif Hilal Vural, shared the following: “The report sheds light on applicable approaches for Türkiye by evaluating international experience with value-based pricing and reimbursement systems across the axes of clinical effectiveness, cost-effectiveness, and hybrid models. The study underscores the importance of considering not only cost factors but also various dimensions of value—such as patient outcomes, contribution to the health system, and societal benefit—in the assessment of health technologies. It also offers assessments regarding the development of a value framework specific to Türkiye, strengthening Health Technology Assessment capacity, improving data infrastructure, and supporting multi-stakeholder participation. The report is expected to contribute to building a shared understanding among different stakeholders in the health ecosystem regarding value-based decision-making processes and to inform future policy discussions.”
IQVIA Türkiye Stakeholder Relations Manager Sercan Mamir said: “During the preparation of the report, international literature on value-based pricing and reimbursement systems, country-specific practices, and current policy approaches were examined comprehensively. The experiences of various countries were evaluated across the axes of clinical effectiveness, cost-effectiveness, and hybrid models, while Türkiye’s existing health system structure, reimbursement mechanisms, and policy priorities were also taken into account. The report goes beyond simply presenting international examples and offers an analytical framework regarding options that may be considered in Türkiye based on these experiences. In this respect, we believe the study will contribute to advancing discussions on value-based systems on a common knowledge base.”
The full report is available via the link.